Sinus tachycardia can be the most probable condition which results into high heart rate above 105 beats/minute. This problem is not very serious and is treatable.
<h3>What is Sinus tachycardia?</h3>
Sinus tachycardia is a type of irregular heartbeat which is characterized by a faster than the normal heart rhythm. The heart's sinus node generates electrical impulses which travels through the heart muscle that causes the heart to beat. A normal sinus rhythm has an average heart rate of the range between 60 and 100 beats/minute.
Treatment is not necessary for sinus tachycardia as it is not a very serious issue. However, if an underlying condition is causing these symptoms, it needs to be treated on time. Treatments for sinus tachycardia include medications such as beta-blockers or calcium channel blockers which can lower the heart rate.
Learn more about Healthy heart here:
brainly.com/question/28178760
#SPJ1
Answer:
False.
Explanation:
Intravenous drug administration consists of applying a drug directly into the patient's vein. This type of drug administration promotes more accurate observations on the drug's effects on the patient's body and on the drug's effectiveness in fighting the disease, mainly because intravenous administration allows the drug to act faster, even when applied in large volumes.
In my opinion I’m mostly recommended that it’s true ?
Confirmatory Tests vary, and may be wrong from time to time. As time passes, the test is not as reliable as stated. If the so called "blood" is on a leather surface, blood isn't too prone to sticking to leather, so it may (or may not) be blood.
Answer:
b) blastic red blood cell (RBC).
Explanation:
In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell <u>(RBC) alloantigens</u> in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology.